chemical

7661/10

7661/10

10 mg

336 USD

7661/10

A 1331852

10 mg

Potent and selective Bcl-xL inhibitor; antitumor and inducer of apoptosis

Bcl-xL

Small Molecules

98%

658.81

?utm_source=labome&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

A 1331852 is a high affinity and selective Bcl-xL inhibitor (Ki 0.01 nM), also inhibits Bcl-W, Bcl-2, and Mcl-1 (Ki values are 4, 6 and 142 nM, respectively). A 1331852 inhibits Bcl-xL-dependent Molt 4 acute lymphoblastic leukemia cell growth in vitro (EC50 = 6 nM). It enhances antitumor effects of Docetaxel (Cat. No. 4056) and Venetoclax (Cat. No. 6960) in xenograft models of breast and lung cancer. A 1331852 also induces apoptosis in and clears senescent biliary epithelial cells (BECs), and induces apoptosis in xenograft models of EBV-associated T- and natural killer cell lymphoma.

Potent and selective Bcl-xL inhibitor; antitumor and inducer of apoptosis

Potent and selective Bcl-xL inhibitor; antitumor and inducer of apoptosis

6-[8-[(2-Benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid

C38H38N6O3S

C38H38N6O3S

1430844-80-6

336 USD

Potent and selective Bcl-xL inhibitor; antitumor and inducer of apoptosis

Apoptosis regulator Bcl-X, bcl2-L-1, BCL2-like 1, bcl-2-like protein 1, BCLXBCL2LBcl-X, bcl-xL, BclxL, BCL-XL/S, bcl-xS, BCLXS, DKFZp781P2092

Store at -20░C